The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10366 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether–lumefantrine

Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine

January 24, 2020 - 14:49 -- Open Access
Author(s): 
Seif Shekalaghe, Dominic Mosha, Ali Hamad, Thabit A. Mbaga, Michael Mihayo, Teun Bousema, Chris Drakeley and Salim Abdulla
Reference: 
Malaria Journal 2020 19:34, 21 January 2020

Primaquine is an important gametocytocidal drug that is combined with conventional malaria treatment for prevention of Plasmodium falciparum malaria transmission. Primaquine has been administered together on the first or the last day of conventional treatment but the impact of primaquine timing has never been examined. This study aimed to assess safety, efficacy and optimal timing of single full-dose (0.75 mg/kg) primaquine when added to a standard 6-dose regimen of artemether–lumefantrine (AL).

In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

January 7, 2020 - 15:14 -- Open Access
Author(s): 
Moussa Lingani, Léa Nadège Bonkian, Halidou Tinto, et al.
Reference: 
Malaria Journal 2020 19:8, 6 January 2020

Artemisinin-based combination therapy (ACT) is recommended to improve malaria treatment efficacy and limit drug-resistant parasites selection in malaria endemic areas. 5 years after they were adopted, the efficacy and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ), the first-line treatments for uncomplicated malaria were assessed in Burkina Faso.

Monitoring of efficacy, tolerability and safety of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial

December 17, 2019 - 16:46 -- Open Access
Author(s): 
Bayode R. Adegbite, Jean R. Edoa, Ayola A. Adegnika, et al.
Reference: 
Malaria Journal 2019 18:424, 16 December 2019

Malaria remains a major public health problem, affecting mainly low-and middle-income countries. The management of this parasitic disease is challenged by ever increasing drug resistance. This study, investigated the therapeutic efficacy, tolerability and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (AS–AQ), used as first-line drugs to treat uncomplicated malaria in Lambaréné, Gabon.

Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial

July 1, 2019 - 15:26 -- Open Access
Author(s): 
Jaishree Raman, Elizabeth Allen, Lesley Workman, Aaron Mabuza, Hendrik Swanepoel, Gillian Malatje, John Frean, Lubbe Wiesner and Karen I. Barnes
Reference: 
Malaria Journal 2019 18:209, 24 June 2019

To reduce onward falciparum malaria transmission, the World Health Organization recommends adding single low-dose (SLD) primaquine to artemisinin-based combination treatment in low transmission areas. However, uptake of this recommendation has been relatively slow given concerns about whether individual risks justify potential community benefit. This study was undertaken to generate comprehensive local data on the risk–benefit profile of SLD primaquine deployment in a pre-elimination area in South Africa.

Country: 
Medical Treatment: 

Non-falciparum malaria imported mainly from Africa: a review from a Portuguese hospital

July 26, 2017 - 15:52 -- Open Access
Author(s): 
Rogério Ruas, André Pinto, João Nuak, António Sarmento and Cândida Abreu
Reference: 
Malaria Journal 2017 16:298, 25 July 2017

NFM remains an important cause of imported malaria in patients from sub-Saharan Africa, alone or as mixed infection with P. falciparum.

Continent: 
Medical Treatment: 

Not Open Access | Can Rapid Diagnostic Testing for Malaria Increase Adherence to Artemether–Lumefantrine?: A Randomized Controlled Trial in Uganda

April 12, 2016 - 16:48 -- NOT Open Access
Author(s): 
Indrani Saran, Elif Yavuz, Howard Kasozi and Jessica Cohen
Reference: 
Am J Trop Med Hyg 2016 vol. 94 no. 4 857-867

We investigated the extent to which uncertainty about malaria diagnosis contributes to patient nonadherence to artemether–lumefantrine (AL) treatment through a randomized controlled trial in central Uganda. Among 1,525 patients purchasing a course of AL at private drug shops, we randomly offered 37.6% a free malaria rapid diagnostic test (RDT) and then assessed adherence through home visits 3 days later. 

Not Open Access | Haemolytic anaemia after oral artemether–lumefantrine treatment in a patient affected by severe imported falciparum malaria

July 30, 2013 - 17:32 -- NOT Open Access
Author(s): 
P. De Nardo, A. Oliva, M. L. Giancola, P. Ghirga, P. Mencarini, M. Bibas, E. Nicastri, A. Antinori, A. Corpolongo
Reference: 
Infection, August 2013, Volume 41, Issue 4, pp 863-865
MalariaWorld

In this paper, we describe the occurrence of haemolysis after oral artemether–lumefantrine treatment.

NOT Open Access | Increased pfmdr1 copy number in Plasmodium falciparum isolates from Suriname

June 24, 2013 - 11:46 -- NOT Open Access
Author(s): 
Mergiory Labadie-Bracho and Malti R. Adhin
Reference: 
Tropical Medicine & International Health, Volume 18, Issue 7, pages 796–799, July 2013
MalariaWorld

Amplification of the pfmdr1 gene is associated with clinical failures and reduced in vivo and in vitro sensitivity to both mefloquine and artemether–lumefantrine in South-East Asia.

Continent: 

Not Open Access | Use of artemether–lumefantrine to treat malaria during pregnancy: what do we know and need to know?

February 21, 2013 - 04:49 -- NOT Open Access
Author(s): 
Theonest K Mutabingwa and Ishag Adam
Reference: 
Expert Review of Anti-infective Therapy, February 2013, Vol. 11, No. 2, Pages 125-135
MalariaWorld

This evaluation addresses drug usage, safety concerns following early exposure, implications for changed pharmacokinetics and reduced parasite susceptibility. Clinical-use updates and strategies to address some knowledge gaps including key operational research are discussed.

Continent: 
Subscribe to RSS - artemether–lumefantrine